Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy

Monday, February 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the positive outcomes of Pevifoscorvir sodium monotherapy in subjects with chronic HBV infection, highlighting significant viral suppression. This development is crucial for patients suffering from this condition, indicating a potential advancement in treatment options. The results suggest a favorable response to the therapy, marking a step forward in managing chronic HBV.
Price reaction · baseline $6.8 (2026-02-20 close) · hit pre-market · 2 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+2.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • High viral suppression observed in chronic HBV infection subjects.
  • Pevifoscorvir sodium monotherapy shows promising results.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is Pevifoscorvir sodium?

Pevifoscorvir sodium is a therapeutic agent used in the treatment of chronic HBV infection.

What were the results of the study on Pevifoscorvir?

The study reported high viral suppression in subjects with chronic HBV infection receiving Pevifoscorvir sodium monotherapy.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare Pevifoscorvir chronic HBV viral suppression HBV treatment
Last updated: Feb 23, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →